查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1522690

特用药品市场：2024-2034

Specialty Pharma Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 264 Pages | 商品交期: 最快1-2个工作天内

价格

预计到2034年，全球特种药品市场规模将以 7.5%的年复合成长率成长。

数位科技与人工智慧推动产业成长

在特种药品领域，数位科技与人工智慧的融合有望带来重大变革。透过实施先进的 IT 平台和人工智慧驱动的解决方案，公司可以提高营运效率，加快生物製药的上市时间，并促进前所未有的创新水准。自动化工作流程和即时资料分析可实现敏捷决策，使企业能够快速利用新的市场机会。

强大的 IT 基础架构利用云端的解决方案来实现安全的资料共享和简化的知识交换，促进全球团队和利害关係人之间的无缝协作。个人化仪表板和行动应用程式透过提供即时见解和可操作的情报来提高客户参与度。这种积极主动的方法不仅可以加强客户关係，还可以提高您公司在动态市场中的竞争力。

此外，数位化使预测分析和机器学习演算法能够优化供应链管理和资源分配，确保更顺畅的营运和成本效率。虚拟临床试验和远距医疗平台利用数位化进步来改善病患招募、参与和整体试验结果，最终加速创新疗法的上市。

特种药品市场也准备好拥抱数位转型，并实现效率、创新和市场扩张的新水准。采用这些技术不仅可以满足当前的需求，还可以帮助公司以敏捷性和远见来应对未来的挑战，塑造一个有弹性和前瞻性的专业製药格局。

本报告调查了全球特种药品市场，提供了市场概况，分析了影响市场成长和市场机会的因素，市场规模推移和预测，各种细分及地区/主要国家的详细分析，竞争形势，主要企业简介等彙整资讯。

目录

第1章 报告概述

第2章 执行摘要

第3章 市场概述

  • 主要发现
  • 市场动态
  • 影响分析
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
  • 供应链分析
  • 监理框架
  • 新兴市场与大趋势
  • 波特五力分析
  • PEST分析

第4章 特殊药物市场分析：依给药途径

  • 主要调查结果
  • 市场吸引力指数
  • 市场规模趋势与预测
  • 口服
  • 非口服
  • 肠内
    • 市场规模趋势与预测：依地区划分
    • 市占率：依地区划分

第5章 特用药品市场分析：依通路

  • 主要调查结果
  • 市场吸引力指数
  • 市场规模趋势与预测
  • 医院
  • 零售药局
  • 专业药房
    • 市场规模趋势与预测：依地区划分
    • 市占率：依地区划分

第6章 特用药物市场分析：依治疗药物分类

  • 主要调查结果
  • 市场吸引力指数
  • 市场规模趋势与预测
  • 肿瘤
  • 免疫
  • 糖尿病
  • 循环系统疾病
  • 呼吸系统
  • 中枢神经系统
  • 其他
    • 市场规模趋势与预测：依地区划分
    • 市占率：依地区划分

第7章 特用药品市场分析：依地区

  • 主要调查结果
  • 市场规模趋势与预测

第8章 北美特用药品市场分析

第9章 欧洲特用药品市场分析

第10章 亚太地区特种药品市场分析

第11章 拉丁美洲特种药品市场分析

第12章 中东与非洲专科药品市场分析

第13章 公司简介

  • 竞争状况
  • 战略展望
  • CVS Health
  • The Cigna Group
  • UnitedHealth Group（Optum, Inc.）
  • Walgreens Boots Alliance, Inc.
  • Humana
  • Teva Pharmaceutical Industries Ltd.
  • Endo, Inc.
  • AbbVie
  • AstraZeneca
  • Amgen Inc.
  • Viatris Inc.
  • Johnson &Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Soleo Health
  • Lumicera

第14章 总结/建议

  • Visiongain的总结
  • 对进入市场的公司的建议
Product Code: PHA1353

The global Specialty Pharma market is projected to grow at a CAGR of 7.5% by 2034

The Specialty Pharma Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Digital Technology and AI Driving Industry Growth

In the realm of specialty pharma, the integration of digital technology and artificial intelligence (AI) promises a profound transformation. Embracing advanced IT platforms and AI-driven solutions empowers companies to enhance operational efficiency, accelerate time-to-market for biopharmaceutical products, and foster unprecedented levels of innovation. Automated workflows and real-time data analytics enable agile decision-making, enabling firms to swiftly capitalize on emerging market opportunities.

A robust IT infrastructure facilitates seamless collaboration across global teams and stakeholders, leveraging cloud-based solutions for secure data sharing and streamlined knowledge exchange. Personalized dashboards and mobile applications elevate client engagement by delivering real-time insights and actionable intelligence. This proactive approach not only enhances customer relationships but also positions companies competitively in a dynamic marketplace.

Moreover, digitalization enables predictive analytics and machine learning algorithms to optimize supply chain management and resource allocation, ensuring smoother operations and cost efficiencies. Virtual clinical trials and telemedicine platforms leverage digital advancements to improve patient recruitment, engagement, and overall trial outcomes, ultimately accelerating the delivery of innovative therapies to market.

As specialty pharma embraces digital transformation, the industry stands poised to unlock new levels of efficiency, innovation, and market expansion. Embracing these technologies not only meets current demands but also prepares companies to navigate future challenges with agility and foresight, shaping a resilient and forward-looking specialty pharma landscape.

Rising Specialty Drug Costs Likely to Challenge Industry Growth

The rising cost of specialty drugs poses a significant challenge to the growth of the specialty drugs market. These medications, often developed for complex and rare conditions, come with hefty price tags that can strain healthcare systems and patients alike. Recent examples highlight these concerns vividly. Firstly, Biogen's Alzheimer's drug, Aduhelm, priced at US$56,000 annually, sparked controversy over its affordability and potential impact on healthcare budgets. Despite its FDA approval, questions persist about whether its benefits justify the high cost.

Similarly, Eisai and Biogen's Leqembi, another Alzheimer's drug priced at $26,500 per year, faces scrutiny for its financial burden on Medicare beneficiaries and the healthcare system. The drug's cost, coupled with its modest efficacy, has raised doubts about its widespread adoption and long-term sustainability.

Moreover, the broader issue of specialty drug pricing extends beyond Alzheimer's treatments. Medications like Entresto, crucial for heart failure patients, also come at significant costs, influencing healthcare expenditure patterns and patient access. These examples underscore the broader challenge facing the specialty drugs market: balancing innovation and access with affordability. As these drugs promise breakthrough treatments for severe conditions, their high prices often limit accessibility, potentially depriving patients of life-changing therapies.

Addressing this challenge requires careful consideration of pricing strategies, reimbursement mechanisms, and policies that ensure equitable access without compromising innovation incentives. Stakeholders, including pharmaceutical companies, policymakers, and insurers, must collaborate to find sustainable solutions that promote both medical progress and patient welfare in an increasingly complex healthcare landscape.

What Questions Should You Ask before Buying a Market Research Report?

How is the Specialty Pharma market evolving?

What is driving and restraining the Specialty Pharma market?

How will each Specialty Pharma submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Specialty Pharma submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Specialty Pharma markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Specialty Pharma projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Specialty Pharma projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Specialty Pharma market?

Where is the Specialty Pharma market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Specialty Pharma market today, and over the next 10 years:

Our 264-page report provides 102 tables and 171 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Specialty Pharma prices and recent developments.

Segments Covered in the Report

Route of Administration

Oral

Parenteral

Rectal

Distribution Channel

Hospitals

Retail Pharmacies

Specialty Pharmacies

Therapeutics

Oncology

Cervical Cancer

Prostate Cancer

Others

Immunology

Arthritis

Crohn's Disease

Ulcerative Colitis

Others

Diabetes

Type 2 Diabetes (Non-insulin)

Type 1 Diabetes & Others

Cardiovascular Disease

Hypertension

Hyperlipidemia

Others

Respiratory

Asthma

COPD

Others

CNS

Neurovascular Diseases

Neurodegenerative Diseases

Mental Health

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Specialty Pharma Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie

Amgen Inc.

AstraZeneca

CVS Health

Endo, Inc.

Humana

Johnson & Johnson

Lumicera

Soleo Health

Sun Pharmaceutical Industries Ltd.

The Cigna Group

Teva Pharmaceutical Industries Ltd.

UnitedHealth Group (Optum, Inc.)

Viatris Inc.

Walgreens Boots Alliance, Inc.

Overall world revenue for Specialty Pharma Market, 2024 to 2034 in terms of value the market will surpass US$330 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Specialty Pharma Market, 2024 to 2034 report help you?

In summary, our 260+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Specialty Pharma Market, 2024 to 2034 Market, with forecasts for route of administration, therapeutics, and distribution channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Specialty Pharma Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Specialty Pharma Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Specialty Pharma Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Specialty Pharma Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Specialty Pharmaceutical Market Surges in Global Spending Landscape
      • 3.3.1.2 Immunology Market Surge Fuels Specialty Pharmaceuticals Growth
      • 3.3.1.3 Expanding Oncology Drug Demand Shapes Specialty Pharma Market Growth
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Challenges of Rising Specialty Drug Costs in Healthcare
      • 3.3.2.2 The Impact of High Drug Costs on Insurance and Specialty Markets
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Advanced Therapies and Innovation Fuelling Specialty Pharma Market Growth
      • 3.3.3.2 Specialty Pharma Seizes Growth Opportunity in Chronic and Rare Diseases
  • 3.4 Supply Chain Analysis
  • 3.5 Regulatory Framework
  • 3.6 Emerging Markets and Megatrends
  • 3.7 Porter's Five Forces Analysis
    • 3.7.1 Bargaining Power of Suppliers
    • 3.7.2 Bargaining Power of Buyers
    • 3.7.3 Competitive Rivalry
    • 3.7.4 Threat of Substitutes
    • 3.7.5 Threat of New Entrants
  • 3.8 PEST Analysis

4 Specialty Pharma Market Analysis Route of Administration

  • 4.1 Key Findings
  • 4.2 Route of Administration Segment: Market Attractiveness Index
  • 4.3 Specialty Pharma Market Size Estimation and Forecast by Route of Administration
  • 4.4 Oral
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Parenteral
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Rectal
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Specialty Pharma Market Analysis Distribution Channel

  • 5.1 Key Findings
  • 5.2 Distribution Channel Segment: Market Attractiveness Index
  • 5.3 Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
  • 5.4 Hospitals
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Retail Pharmacies
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Specialty Pharmacies
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Specialty Pharma Market Analysis by Therapeutics

  • 6.1 Key Findings
  • 6.2 Therapeutics Segment: Market Attractiveness Index
  • 6.3 Specialty Pharma Market Size Estimation and Forecast by Therapeutics
  • 6.4 Oncology
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
    • 6.4.3 Oncology Market Size by Type
      • 6.4.3.1 Cervical Cancer
      • 6.4.3.2 Prostate Cancer
      • 6.4.3.3 Others
  • 6.5 Immunology
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
    • 6.5.3 Immunology Market Size by Type
      • 6.5.3.1 Arthritis
      • 6.5.3.2 Crohn's Disease
      • 6.5.3.3 Ulcerative Colitis
      • 6.5.3.4 Others
  • 6.6 Diabetes
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
    • 6.6.3 Diabetes Market Size by Type
      • 6.6.3.1 Type 2 Diabetes (Non-insulin)
      • 6.6.3.2 Type 1 Diabetes & Others
  • 6.7 Cardiovascular Disease
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)
    • 6.7.3 Cardiovascular Disease Market Size by Type
      • 6.7.3.1 Hypertension
      • 6.7.3.2 Hyperlipidaemia
      • 6.7.3.3 Others
  • 6.8 Respiratory
    • 6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.8.2 Market Share by Region, 2024 & 2034 (%)
    • 6.8.3 Respiratory Market Size by Type
      • 6.8.3.1 Asthma
      • 6.8.3.2 COPD
      • 6.8.3.3 Others
  • 6.9 CNS
    • 6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.9.2 Market Share by Region, 2024 & 2034 (%)
    • 6.9.3 CNS Market Size by Type
      • 6.9.3.1 Neurovascular Diseases
      • 6.9.3.2 Neurodegenerative Diseases
      • 6.9.3.3 Mental Health
  • 6.10 Others
    • 6.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.10.2 Market Share by Region, 2024 & 2034 (%)

7 Specialty Pharma Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America Specialty Pharma Market Analysis

  • 8.1 Key Findings
  • 8.2 North America Specialty Pharma Market Attractiveness Index
  • 8.3 North America Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 8.4 North America Specialty Pharma Market Size Estimation and Forecast by Country
  • 8.5 North America Specialty Pharma Market Size Estimation and Forecast by Route of Administration
  • 8.6 North America Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
  • 8.7 North America Specialty Pharma Market Size Estimation and Forecast by Therapeutics
  • 8.8 U.S. Specialty Pharma Market Analysis
  • 8.9 Canada Specialty Pharma Market Analysis

9 Europe Specialty Pharma Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe Specialty Pharma Market Attractiveness Index
  • 9.3 Europe Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 Europe Specialty Pharma Market Size Estimation and Forecast by Country
  • 9.5 Europe Specialty Pharma Market Size Estimation and Forecast by Route of Administration
  • 9.6 Europe Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
  • 9.7 Europe Specialty Pharma Market Size Estimation and Forecast by Therapeutics
  • 9.8 Germany Specialty Pharma Market Analysis
  • 9.9 France Specialty Pharma Market Analysis
  • 9.10 UK Specialty Pharma Market Analysis
  • 9.11 Italy Specialty Pharma Market Analysis
  • 9.12 Spain Specialty Pharma Market Analysis
  • 9.13 Rest of Europe Specialty Pharma Market Analysis

10 Asia Pacific Specialty Pharma Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific Specialty Pharma Market Attractiveness Index
  • 10.3 Asia Pacific Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Route of Administration
  • 10.6 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
  • 10.7 Asia Pacific Specialty Pharma Market Size Estimation and Forecast by Therapeutics
  • 10.8 Japan Specialty Pharma Market Analysis
  • 10.9 China Specialty Pharma Market Analysis
  • 10.10 India Specialty Pharma Market Analysis
  • 10.11 Australia Specialty Pharma Market Analysis
  • 10.12 South Korea Specialty Pharma Market Analysis
  • 10.13 Rest of Asia Pacific Specialty Pharma Market Analysis

11 Latin America Specialty Pharma Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America Specialty Pharma Market Attractiveness Index
  • 11.3 Latin America Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Latin America Specialty Pharma Market Size Estimation and Forecast by Country
  • 11.5 Latin America Specialty Pharma Market Size Estimation and Forecast by Route of Administration
  • 11.6 Latin America Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
  • 11.7 Latin America Specialty Pharma Market Size Estimation and Forecast by Therapeutics
  • 11.8 Brazil Specialty Pharma Market Analysis
  • 11.9 Mexico Specialty Pharma Market Analysis
  • 11.10 Rest of Latin America Specialty Pharma Market Analysis

12 MEA Specialty Pharma Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA Specialty Pharma Market Attractiveness Index
  • 12.3 MEA Specialty Pharma Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 MEA Specialty Pharma Market Size Estimation and Forecast by Country
  • 12.5 MEA Specialty Pharma Market Size Estimation and Forecast by Route of Administration
  • 12.6 MEA Specialty Pharma Market Size Estimation and Forecast by Distribution Channel
  • 12.7 MEA Specialty Pharma Market Size Estimation and Forecast by Therapeutics
  • 12.8 GCC Specialty Pharma Market Analysis
  • 12.9 South Africa Specialty Pharma Market Analysis
  • 12.10 Rest of MEA Specialty Pharma Market Analysis

13 Company Profiles

  • 13.1 Competitive Landscape, 2023
  • 13.2 Strategic Outlook
  • 13.3 CVS Health
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2019-2023
      • 13.3.3.2 Business Segment Market Shares, 2023
    • 13.3.4 Product Benchmarking
    • 13.3.5 SWOT Analysis
  • 13.4 The Cigna Group
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Financial Analysis
      • 13.4.3.1 Net Revenue, 2019-2023
      • 13.4.3.2 Business Segment Market Shares, 2023
    • 13.4.4 Product Benchmarking
    • 13.4.5 SWOT Analysis
  • 13.5 UnitedHealth Group (Optum, Inc.)
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Financial Analysis
      • 13.5.3.1 Net Revenue, 2019-2023
      • 13.5.3.2 Business Segment Market Shares, 2023
    • 13.5.4 Product Benchmarking
    • 13.5.5 Strategic Outlook
    • 13.5.6 SWOT Analysis
  • 13.6 Walgreens Boots Alliance, Inc.
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Financial Analysis
      • 13.6.3.1 Net Revenue, 2019-2023
      • 13.6.3.2 Regional Market Shares, 2023
      • 13.6.3.3 Business Segment Market Shares, 2023
    • 13.6.4 Product Benchmarking
    • 13.6.5 Strategic Outlook
    • 13.6.6 SWOT Analysis
  • 13.7 Humana
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Financial Analysis
      • 13.7.3.1 Net Revenue, 2019-2023
      • 13.7.3.2 Business Segment Market Shares, 2023
    • 13.7.4 Product Benchmarking
  • 13.8 Teva Pharmaceutical Industries Ltd.
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Financial Analysis
      • 13.8.3.1 Net Revenue, 2019-2023
      • 13.8.3.2 R&D, 2019-2023
      • 13.8.3.3 Regional Market Shares, 2023
    • 13.8.4 Product Benchmarking
    • 13.8.5 Strategic Outlook
  • 13.9 Endo, Inc.
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Product Benchmarking
  • 13.10 AbbVie
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2019-2023
      • 13.10.3.2 R&D, 2019-2023
      • 13.10.3.3 Regional Market Shares, 2023
      • 13.10.3.4 Business Segment Market Shares, 2023
    • 13.10.4 Product Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 AstraZeneca
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2019-2023
      • 13.11.3.2 R&D, 2019-2023
      • 13.11.3.3 Regional Market Shares, 2023
    • 13.11.4 Product Benchmarking
  • 13.12 Amgen Inc.
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Financial Analysis
      • 13.12.3.1 Net Revenue, 2019-2023
      • 13.12.3.2 R&D, 2019-2023
      • 13.12.3.3 Regional Market Shares, 2023
    • 13.12.4 Product Benchmarking
    • 13.12.5 Strategic Outlook
  • 13.13 Viatris Inc.
    • 13.13.1 Company Snapshot
    • 13.13.2 Company Overview
    • 13.13.3 Financial Analysis
      • 13.13.3.1 Net Revenue, 2019-2023
      • 13.13.3.2 R&D, 2019-2023
      • 13.13.3.3 Regional Market Shares, 2023
    • 13.13.4 Product Benchmarking
  • 13.14 Johnson & Johnson
    • 13.14.1 Company Snapshot
    • 13.14.2 Company Overview
    • 13.14.3 Financial Analysis
      • 13.14.3.1 Net Revenue, 2019-2023
      • 13.14.3.2 R&D, 2019-2023
      • 13.14.3.3 Regional Market Shares, 2023
      • 13.14.3.4 Business Segment Market Shares, 2023
    • 13.14.4 Product Benchmarking
  • 13.15 Sun Pharmaceutical Industries Ltd.
    • 13.15.1 Company Snapshot
    • 13.15.2 Company Overview
    • 13.15.3 Financial Analysis
      • 13.15.3.1 Net Revenue, 2020-2024
    • 13.15.4 Product Benchmarking
    • 13.15.5 Strategic Outlook
  • 13.16 Soleo Health
    • 13.16.1 Company Snapshot
    • 13.16.2 Company Overview
    • 13.16.3 Product Benchmarking
    • 13.16.4 Strategic Outlook
  • 13.17 Lumicera
    • 13.17.1 Company Snapshot
    • 13.17.2 Company Overview
    • 13.17.3 Product Benchmarking

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from Visiongain
  • 14.2 Recommendations for Market Players

List of Tables

  • Table 1 Specialty Pharma Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
  • Table 2 Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 3 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 4 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 5 Rectal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 6 Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 7 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 8 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 9 Specialty Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 10 Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 11 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 12 Oncology Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 13 Immunology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 14 Immunology Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 15 Diabetes Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 16 Diabetes Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 17 Cardiovascular Disease Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 18 Cardiovascular Disease Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 19 Respiratory Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 20 Respiratory Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 21 CNS Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 22 CNS Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 23 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 24 Specialty Pharma Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 25 North America Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 26 North America Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 27 North America Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 28 North America Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 29 U.S. Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 30 Canada Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 31 Europe Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR %)
  • Table 32 Europe Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 33 Europe Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 34 Europe Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 35 Germany Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 36 France Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 37 UK Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 38 Italy Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 39 Spain Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 40 Rest of Europe Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 41 Asia Pacific Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 42 Asia Pacific Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 43 Asia Pacific Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 44 Asia Pacific Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 45 Japan Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 46 China Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 47 India Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 48 Australia Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 49 South Korea Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 50 Rest of Asia Pacific Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 51 Latin America Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 52 Latin America Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 53 Latin America Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 54 Latin America Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 55 Brazil Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 56 Mexico Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 57 Rest of Latin America Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 58 MEA Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 59 MEA Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 60 MEA Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 61 MEA Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 62 GCC Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 63 South Africa Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 64 Rest of MEA Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 65 Strategic Outlook
  • Table 66 CVS Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 67 CVS Health: Product Benchmarking
  • Table 68 The Cigna Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 69 The Cigna Group: Product Benchmarking
  • Table 70 UnitedHealth Group. (Optum, Inc.): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 71 UnitedHealth Group. (Optum, Inc.): Product Benchmarking
  • Table 72 UnitedHealth Group. (Optum, Inc.): Strategic Outlook
  • Table 73 Walgreens Boots Alliance, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 74 Walgreens Boots Alliance, Inc.: Product Benchmarking
  • Table 75 Walgreens Boots Alliance, Inc.: Strategic Outlook
  • Table 76 Humana: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 77 Humana: Product Benchmarking
  • Table 78 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 80 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 81 Endo, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Endo, Inc.: Product Benchmarking
  • Table 83 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84 AbbVie: Product Benchmarking
  • Table 85 AbbVie: Strategic Outlook
  • Table 86 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 87 AstraZeneca: Product Benchmarking
  • Table 88 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Amgen Inc.: Product Benchmarking
  • Table 90 Amgen Inc.: Strategic Outlook
  • Table 91 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Viatris Inc.: Product Benchmarking
  • Table 93 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Johnson & Johnson: Product Benchmarking
  • Table 95 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 97 Sun Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 98 Soleo Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Soleo Health: Product Benchmarking
  • Table 100 Soleo Health: Strategic Outlook
  • Table 101 Lumicera: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Lumicera: Product Benchmarking

List of Figures

  • Figure 1 Specialty Pharma Market Segmentation
  • Figure 2 Specialty Pharma Market by Route of Administration: Market Attractiveness Index
  • Figure 3 Specialty Pharma Market by Distribution Channel: Market Attractiveness Index
  • Figure 4 Specialty Pharma Market by Therapeutics: Market Attractiveness Index
  • Figure 5 Specialty Pharma Market Attractiveness Index by Region
  • Figure 6 Specialty Pharma Market: Market Dynamics
  • Figure 7 Specialty Pharma Market: Impact Analysis
  • Figure 8 Share of Specialty Products in Global Pharmaceutical Spending
  • Figure 9 Global Pharmaceutical Spending, US$ Billion (2013 - 2027)
  • Figure 10 Global New Incidences of New Cancer Cases per 100,000 People
  • Figure 11 Global Cancer Cases by Country, 2022
  • Figure 12 Specialty Pharma Industry: Supply Chain Analysis
  • Figure 13 Specialty Pharma Market: Porter's Five Forces Analysis
  • Figure 14 Specialty Pharma Market: PEST Analysis
  • Figure 15 Specialty Pharma Market Route of Administration: Market Attractiveness Index
  • Figure 16 Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 17 Specialty Pharma Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
  • Figure 18 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 19 Oral Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 20 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 21 Parenteral Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 22 Rectal Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 23 Rectal Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 24 Specialty Pharma Market Distribution Channel: Market Attractiveness Index
  • Figure 25 Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 26 Specialty Pharma Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
  • Figure 27 Hospitals Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 28 Hospitals Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 30 Retail Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Specialty Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 32 Specialty Pharmacies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Specialty Pharma Market by Therapeutics: Market Attractiveness Index
  • Figure 34 Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
  • Figure 35 Specialty Pharma Market Share Forecast by Therapeutics, 2024, 2029, 2034 (%)
  • Figure 36 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 37 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 38 Oncology Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 39 Oncology Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 40 Immunology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 41 Immunology Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 42 Immunology Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 43 Immunology Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 44 Diabetes Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 45 Diabetes Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Diabetes Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 47 Diabetes Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 48 Cardiovascular Disease Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 49 Cardiovascular Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Cardiovascular Diseases Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 51 Cardiovascular Diseases Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 52 Respiratory Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 53 Respiratory Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Respiratory Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 55 Respiratory Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 56 CNS Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 57 CNS Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 58 CNS Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 59 CNS Market Share Forecast by Type, 2024, 2029, 2034 (%)
  • Figure 60 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 61 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 62 Specialty Pharma Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
  • Figure 63 Specialty Pharma Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 64 Specialty Pharma Market by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 65 North America Specialty Pharma Market Attractiveness Index
  • Figure 66 North America Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 67 North America Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 68 North America Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 69 North America Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 70 North America Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 71 North America Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 72 North America Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 73 North America Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
  • Figure 74 North America Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
  • Figure 75 U.S. Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 76 Canada Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 77 Europe Specialty Pharma Market Attractiveness Index
  • Figure 78 Europe Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 79 Europe Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 80 Europe Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 81 Europe Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 82 Europe Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 83 Europe Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 84 Europe Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 85 Europe Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
  • Figure 86 Europe Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
  • Figure 87 Germany Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 88 France Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 89 UK Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 90 Italy Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 91 Spain Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 92 Rest of Europe Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 93 Asia Pacific Specialty Pharma Market Attractiveness Index
  • Figure 94 Asia Pacific Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 95 Asia Pacific Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 96 Asia Pacific Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 97 Asia Pacific Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 98 Asia Pacific Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 99 Asia Pacific Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 100 Asia Pacific Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 101 Asia Pacific Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
  • Figure 102 Asia Pacific Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
  • Figure 103 Japan Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 104 China Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 105 India Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 106 Australia Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 107 South Korea Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 108 Rest of Asia Pacific Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 109 Latin America Specialty Pharma Market Attractiveness Index
  • Figure 110 Latin America Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 111 Latin America Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 112 Latin America Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 113 Latin America Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 114 Latin America Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 115 Latin America Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 116 Latin America Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 117 Latin America Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
  • Figure 118 Latin America Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
  • Figure 119 Brazil Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 120 Mexico Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 121 Rest of Latin America Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 122 MEA Specialty Pharma Market Attractiveness Index
  • Figure 123 MEA Specialty Pharma Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 124 MEA Specialty Pharma Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 125 MEA Specialty Pharma Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 126 MEA Specialty Pharma Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
  • Figure 127 MEA Specialty Pharma Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 128 MEA Specialty Pharma Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
  • Figure 129 MEA Specialty Pharma Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 130 MEA Specialty Pharma Market Forecast by Therapeutics, 2024-2034 (US$ Billion, AGR %)
  • Figure 131 MEA Specialty Pharma Market Share Forecast by Therapeutics, 2024 & 2034 (%)
  • Figure 132 GCC Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 133 South Africa Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 134 Rest of MEA Specialty Pharma Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 135 Specialty Pharma Market: Company Share/Ranking, 2023
  • Figure 136 CVS Health: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 137 CVS Health: Business Segment Market Shares, 2023
  • Figure 138 CVS Health: SWOT Analysis
  • Figure 139 The Cigna Group: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 140 The Cigna Group: Business Segment Market Shares, 2023
  • Figure 141 The Cigna Group: SWOT Analysis
  • Figure 142 UnitedHealth Group. (Optum, Inc.): Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 143 UnitedHealth Group. (Optum, Inc.): Business Segment Market Shares, 2023
  • Figure 144 UnitedHealth Group. (Optum, Inc.): SWOT Analysis
  • Figure 145 Walgreens Boots Alliance, Inc.: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 146 Walgreens Boots Alliance, Inc.: Regional Market Shares, 2023
  • Figure 147 Walgreens Boots Alliance, Inc.: Business Segment Market Shares, 2023
  • Figure 148 Walgreens Boots Alliance, Inc.: SWOT Analysis
  • Figure 149 Humana: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 150 Humana: Business Segment Market Shares, 2023
  • Figure 151 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 152 Teva Pharmaceutical Industries Ltd.: R&D, 2019-2023 (US$ Billion, AGR %)
  • Figure 153 Teva Pharmaceutical Industries Ltd.: Regional Market Shares, 2023
  • Figure 154 AbbVie: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 155 AbbVie: R&D, 2019-2023 (US$ Billion, AGR %)
  • Figure 156 AbbVie: Regional Market Shares, 2023
  • Figure 157 AbbVie: Business Segment Market Shares, 2023
  • Figure 158 AstraZeneca: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 159 AstraZeneca: R&D, 2019-2023 (US$ Billion, AGR %)
  • Figure 160 AstraZeneca: Regional Market Shares, 2023
  • Figure 161 Amgen Inc.: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 162 Amgen Inc.: R&D, 2019-2023 (US$ Billion, AGR %)
  • Figure 163 Amgen Inc.: Regional Market Shares, 2023
  • Figure 164 Viatris Inc.: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 165 Viatris Inc.: R&D, 2019-2023 (US$ Billion, AGR %)
  • Figure 166 Viatris Inc.: Regional Market Shares, 2023
  • Figure 167 Johnson & Johnson: Net Revenue, 2019-2023 (US$ Billion, AGR %)
  • Figure 168 Johnson & Johnson: R&D, 2019-2023 (US$ Billion, AGR %)
  • Figure 169 Johnson & Johnson: Regional Market Shares, 2023
  • Figure 170 Johnson & Johnson: Business Segment Market Shares, 2023
  • Figure 171 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2020-2024 (US$ Billion, AGR %)